Semaglutide | Peptide Reference Material
RESEARCH PEPTIDE

Semaglutide | Peptide Reference Material

Long-Acting GLP-1 Receptor Agonist Analogue — Research Peptide
$59.00
Long-acting GLP-1 receptor agonist analogue supplied as a lyophilized laboratory reference material. Research use only. Not for human or veterinary use.
✓ Identity Verified
✓ Batch Documentation
✓ QR Lot Verification
✓ Research Use Only
✓ U.S. Fulfillment
✓ Batch Verification Available View verification →
Lot Verification Variant-specific documentation
Traceable Lots VBL lot identification
Primary Literature Peer-reviewed sources
Research Use Only Laboratory research materials

Scientific Specifications

Reference characteristics for laboratory research materials.

CAS Number
910463-68-2
Purity
≥98%
Molecular Formula
C187H291N45O59
Molecular Weight
4113.64
Appearance
White lyophilized powder
Storage
-20°C
Research Classification
Research Use Only (RUO). Not for human or veterinary use.

SCIENTIFIC OVERVIEW

Scientific background and research classification for this laboratory reference material.

Semaglutide is a long-acting analogue of human glucagon-like peptide-1 (GLP-1) engineered for extended duration of action. Compared with native GLP-1(7-37), it carries two amino-acid substitutions (Aib at position 8 and Arg at position 34) and is derivatized at lysine 26 with a C18 fatty-diacid moiety via a hydrophilic spacer, a design that confers high albumin binding and stability against DPP-4-mediated degradation (Lau et al., J Med Chem 2015).

This material is supplied as a lyophilized research peptide for in-vitro and preclinical laboratory investigation only.

Primary Research Category
Metabolic Research
Material Type
Lyophilized Peptide
Intended Use
Laboratory Research
Research Categories
Receptor Pharmacology Energy Homeostasis Glucose Metabolism Weight Management

Mechanism of Action

Molecular interaction profile describing how this research material engages receptor systems and influences downstream biological signaling pathways.

Published receptor assays characterize selective GLP-1R agonism and cAMP signaling. Albumin association and DPP-4 stability are properties studied for the modified structure; clinical outcomes are not attributed to this material.

Molecular Targets
  • Glucagon-Like Peptide-1 Receptor (GLP-1R)
Biological Pathways
  • GLP-1 Signaling
  • Insulin Signaling
  • Glucose Uptake
Primary Organ Systems
  • Endocrine System
  • Gastrointestinal System
  • Central Nervous System
  • Metabolic System

Research Documentation

Laboratory documentation is presented when available for the selected product specification and current lot.

Batch Verified
Independent Batch Verification

Independent laboratory verification for this batch:

  • Identity Confirmation
  • HPLC Purity Analysis
  • Net Peptide Content
  • Endotoxin Testing
  • Analytical Chromatogram
  • Independent Laboratory Verification
View Batch Verification →
Scientific References
Peer-Reviewed Literature

Explore published literature, clinical investigations, and foundational scientific research.

View References →
Laboratory Resources
Technical Guidance

Storage guidance, handling recommendations, analytical methods, and laboratory best practices.

Related Research
Companion Materials

Discover complementary research materials frequently studied alongside this compound.

Research Center

Scientific literature, laboratory resources, and related materials curated to support research involving this research material.

Scientific References
Peer-Reviewed Literature

Explore curated publications from peer-reviewed journals including clinical investigations, mechanistic studies, and foundational scientific literature.

Browse References →
Scientific Dossier
Deeper Technical Treatment

Comprehensive scientific documentation including literature review, mechanism, pharmacology, and study data for this research material.

Laboratory Resources
Technical Guidance

Storage guidance, handling information, analytical standards, research policies, and laboratory support documentation.

Research Library

Curated peer-reviewed literature selected to provide scientific context for this research material.

Pharmacology Study•Journal of Medicinal Chemistry• 2015

Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

Discovery/design study describing semaglutide's structure (Aib8, Arg34 substitutions; lysine-26 C18 fatty-diacid derivatization), sub-nanomolar GLP-1R affinity (0.38 ± 0.06 nM), high albumin binding, and extended preclinical pharmacokinetics (i.v. half-life 46.1 h in mini-pigs) supporting once-weekly dosing design.
Velora Research Insight
Defines the molecular design and receptor pharmacology that make semaglutide a reference long-acting GLP-1R agonist in laboratory research.
PubMed →DOI →
Clinical Trial•New England Journal of Medicine• 2016

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

SUSTAIN-6 (NCT01720446): randomized, placebo-controlled trial in 3,297 adults with type 2 diabetes at high cardiovascular risk; the composite of cardiovascular death, nonfatal MI, or nonfatal stroke occurred in 6.6% with once-weekly semaglutide versus 8.9% with placebo (HR 0.74; 95% CI 0.58-0.95), with higher retinopathy complications and gastrointestinal discontinuations reported.
Velora Research Insight
Anchors the published cardiovascular-outcome evidence for GLP-1R agonism in type 2 diabetes research contexts.
PubMed →DOI →
Clinical Trial•New England Journal of Medicine• 2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

STEP 1 (NCT03548935): double-blind phase 3 trial in 1,961 adults with overweight or obesity without diabetes; mean body-weight change −14.9% with semaglutide 2.4 mg weekly versus −2.4% with placebo at week 68 (difference −12.4 percentage points), with transient gastrointestinal events most common.
Velora Research Insight
Provides the benchmark published body-weight endpoint data for GLP-1R agonist research models.
PubMed →DOI →
Clinical Trial•New England Journal of Medicine• 2023

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

SELECT (NCT03574597): event-driven, randomized, placebo-controlled superiority trial in 17,604 adults with overweight or obesity and established cardiovascular disease without diabetes; major adverse cardiovascular events occurred in 6.5% with semaglutide 2.4 mg weekly versus 8.0% with placebo (HR 0.80; 95% CI 0.72-0.90) over a mean 39.8-month follow-up.
Velora Research Insight
Extends the published cardiovascular-outcome evidence for GLP-1R agonism to a non-diabetic research population.
PubMed →DOI →